Thrombolytic therapy: State of the art

Thrombosis Research

Volumn 103, Issue SUPPL. 1, 2001, Pages

  Sinnaeve, Peter ^a   Van de Werf, Frans ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Acute myocardial infarction; Thrombolytic therapy

Indexed keywords

ABCIXIMAB; FIBRIN; FIBRINOLYTIC AGENT; HEPARIN; HIRULOG; LANOTEPLASE; PLASMINOGEN ACTIVATOR INHIBITOR; RETEPLASE; SARUPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; FIBRINOLYTIC THERAPY; HUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL;

ANTIFIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY;

EID: 0035975627     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(01)00301-2     Document Type: Article

References (46)

1. Intravenous NPA for the treatment of infarcting myocardium early. In TIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction
2. Thrombolysis medication errors: Benefits of bolus thrombolytic agents
3. Meta-analysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction
4. Pharmacokinetics and pharmacodynamics of tenecteplase: Results from a phase II study in patients with acute myocardial infarction
5. Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective
6. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: A double-blind, randomized angiographic trial of lanoteplase versus alteplase
7. Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase
8. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes
9. Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction
10. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction
11. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction
12. Randomised, double-blind comparison reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence
13. A comparison of reteplase with alteplase for acute myocardial infarction
14. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: Results from the global utilization of streptokinase and t-PA for occluded coronary arteries (GUSTO) III trial
15. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment
16. Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator
17. The relative rapidity of recanalization induced by recombinant tissue-type plasminogen activator (r-tPA) and TNK-tPA, assessed with enzymatic methods
18. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog
19. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial
20. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial
21. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial
22. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial
23. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator
24. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: A comparison of TNK-tpa and rt-PA
25. Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA)
26. Comparison of thrombolytic therapies with mutant tPA (lanoteplase/SUN9216) and recombinant tPA (alteplase) for acute myocardial infarction
27. In TIME-II: More than a study on lanoteplase
28. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction
29. Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS)
30. Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction
31. Saruplase in myocardial infarction
32. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction
33. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: The COMPASS Equivalence Trial
34. Bolus Administration of Saruplase in Europe (BASE), a pilot study in patients with acute myocardial infarction
35. Thrombin plays a pivotal role in vascular re-occlusion after PTCA and coronary thrombolysis
36. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: Results from TIMI (Thrombolysis in Myocardial Infarction) 14
37. Combination reperfusion therapy with abciximab and reduced dose reteplase: Results from TIMI 14
38. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
39. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4 Pilot)
40. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy
41. Comparison of usefulness of computer assisted continuous 48-h 3-lead with 12-lead ECG ischaemia monitoring for detection and quantitation of ischaemia in patients with unstable angina
42. Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram
43. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model
44. A tissue plasminogen activator/P-selectin fusion protein is an effective thrombolytic agent
45. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons
46. Staphylokinase as a plasminogen activator component in recombinant fusion proteins